ABSTRACT BACKGROUND Pathogenesis and diagnostic biomarkers for diseases can be discovered by metabolomic profiling of
. UA and AMI are also referred to as acute coronary syndrome (ACS).
If the molecular mechanisms of CAD could be deciphered, its incidence and associated mortality might be reduced. Multiple, complex molecular events characterize the progression of CAD. Atherosclerosis, a common cause of angina and AMI, is a slow and complicated process (3) . What exactly causes plaque, how plaque develops over time, and why plaque dislodges to form a clot are largely unknown. Experimental models of atherogenesis provide information about the molecular mechanisms of plaque growth. Nevertheless, the transition from coronary stability to instability is less well understood because animal models of this progression are unavailable (4).
With early screening and differential diagnosis of CAD, optimal patient-specific therapies can be initiated. The current clinical diagnosis differentiates between the types of CAD on the basis of symptoms, electrocardiogram (ECG), cardiac markers, stress testing, and coronary angiography (5) (6) (7) . Among these methods, invasive coronary angiography is the diagnostic "gold standard" (8) , but its specialized technology and high cost limit it to a select population (5) .
On the one hand, a sizable portion of individuals who underwent invasive angiography had been shown to have normal coronary arteries (9) . On the other hand, episodes of myocardial ischemia or infarction are possible after atypical symptoms in some patients with CAD, especially in patients who are elderly or have diabetes (10) .
Abnormal metabolism also characterizes CAD.
Metabolic alterations in the heart result in changes in the metabolome of biofluids (11) . Metabolites could clarify pathogenesis for potential therapeutic targets.
A combination of multiple small-molecule metabolites may offer excellent diagnostic values (12) .
Metabolomics, a rapidly expanding field in systems biology, measures metabolic alterations in response to disease progression (12) . Plasma, a frequently considered pool of metabolites, has been a source for metabolic profiling (13) . Liquid chromatography mass spectrometry provides the most compatible technique for sensitive detection of small-molecule metabolites with robust reliability and reproducibility (14, 15) . This work describes a comprehensive metabolomic evaluation for identifying types of CAD. Fan et al.
METHODS
Metabolomics of Coronary Artery Disease S E P T E M B E R 2 0 , 2 0 1 6 : Table 1 . Compared with NCA subjects, CAD patients had higher levels of hemoglobin, glucose, and estimated glomerular filtration rate, but lower levels of total cholesterol as well as low-and high-density lipoprotein cholesterol.
CAD patients were older than subjects without coronary diseases, although there were no statistically significant differences in age among the patient groups. The percentage of females was lower among CAD patients than in NCA subjects.
The test phase from center 1 included 933 participants. Their baseline characteristics are shown in
Online Table 1 , and numbers participating in the external validation phase are shown in Figure 1 . Tables 2 to 4 . Fan et al. Table 5 and
Demographic information of external validation batches is shown in Online
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Online Figure 4 , respectively. 
Differential metabolites
This study, involving 2,324 patients with suspected heart disease, included both discovery and validation phases. ACS ¼ acute coronary syndrome; AMI ¼ acute myocardial infarction; NCA ¼ normal coronary artery; NOCA ¼ nonobstructive coronary atherosclerosis; SA ¼ stable angina; UA ¼ unstable angina.
Fan et al.
Metabolomics of Coronary Artery Disease Num t [1] to [1] NOCA vs. NCA Fan et al.
Metabolomics of Coronary Artery Disease S E P T E M B E R 2 0 , 2 0 1 6 : 1 2 8 1 -9 3 CAD groups and had highly correlated coefficients.
Levels of some correlated amino acids were upregulated. Short-chain acylcarnitines, in the center of the network, bridged the altered metabolites.
Metabolites of bile acids decreased. The disturbed metabolic pathways are detailed in Online Figure 6 on the basis of the KEGG Pathway Database.
DIFFERENTIAL DIAGNOSIS OF METABOLIC BIOMARKERS.
Accurate diagnosis of the stage of CAD is fundamental for personalized treatment of coronary disease. For differential diagnosis, the criteria of metabolomicsbased biomarkers are VIP >1.5 and adjusted p value <0.05. As summarized in Table 2 , there were 10 specific metabolic biomarkers for distinguishing Table 9 .
On the basis of the highest prediction sensitivity and specificity of the ROC in the discovery phase, the optimal cut-off values were 0.635 for NOCA versus NCA, 0.205 for SA versus NOCA, 0.692 for UA versus other abbreviations as in Figure 1 .
JACC VOL. 68, NO. 12, 2016 Fan et al. Odds ratios of the 12 biomarker panels after adjustment for possible confounding comorbidities, and Patients suspected with coronary artery disease (CAD) underwent coronary angiography and were divided into appropriate groups: normal coronary artery (NCA), nonobstructive coronary atherosclerosis (NOCA), stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI). The metabolomic profiles were determined by liquid chromatography-mass spectrometry (LC-MS). Differential metabolites were identified by multivariate statistics. The specific metabolic pathways were characterized using significant CAD (NCA/NOCA) versus nonsignificant CAD (SA/UA/AMI) as an example. The significantly changed metabolites were used for differential diagnosis. Orthogonal projection to latent structure-discriminant analysis (OPLS-DA) score plot showed clear discrimination between significant versus nonsignificant CAD. Receiver-operating characteristic (ROC) analysis provided area under the curve (AUC) of 0.938 with sensitivity of 83.3% and specificity of 91.6% in the discovery phase, and offered a predictive value of 93.0% in the test phase and 100.0% in the 3-centered external validation sets.
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metabolic biomarkers we discovered were much higher than reported with noninvasive methods such as coronary computed tomographic angiography (33) .
These biomarkers separate individuals who may benefit from additional testing with invasive angiography from individuals who will not.
STUDY LIMITATIONS. First, the use of this technique could exclude other classes of lipids and amino acids.
A dual analytical platform, such as gas chromatography mass spectrometry together with liquid chromatography-mass spectrometry, is recommended in future studies. Second, because of lacking a centralized core laboratory, it is possible there were siteto-site and observer-to-observer variations in the adjudication of coronary stenosis. Third, our study population consisted of middle-aged to elderly Chinese patients. In future studies, the scope could be broadened to include other ethnicities within Asia and other races such as Caucasians and Africans.
Younger age groups suspected of or confirmed with CAD could be considered.
CONCLUSIONS
We reported a comprehensive metabolomic evalua- 
